KR101403311B1 - 레닌 억제제로서의 3,4-치환된 피페리딘 유도체 - Google Patents

레닌 억제제로서의 3,4-치환된 피페리딘 유도체 Download PDF

Info

Publication number
KR101403311B1
KR101403311B1 KR1020107024856A KR20107024856A KR101403311B1 KR 101403311 B1 KR101403311 B1 KR 101403311B1 KR 1020107024856 A KR1020107024856 A KR 1020107024856A KR 20107024856 A KR20107024856 A KR 20107024856A KR 101403311 B1 KR101403311 B1 KR 101403311B1
Authority
KR
South Korea
Prior art keywords
alkylene
methyl
unsubstituted
halogens
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020107024856A
Other languages
English (en)
Korean (ko)
Other versions
KR20100131007A (ko
Inventor
오스틴 츠-위 천
다니엘 듀브
피에르-앙드레 푸르니에
에리히 엘. 그림
패트릭 라콤브
세바스찬 라리버트
드와이트 맥도날드
디. 브루스 맥케이
다니엘 제임스 맥카이
톰 야오-쓰앙 우
루이스-찰스 캠포
제레미 피터 스코트
나디네 브레메이어
Original Assignee
액테리온 파마슈티칼 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 액테리온 파마슈티칼 리미티드 filed Critical 액테리온 파마슈티칼 리미티드
Publication of KR20100131007A publication Critical patent/KR20100131007A/ko
Application granted granted Critical
Publication of KR101403311B1 publication Critical patent/KR101403311B1/ko
Assigned to 이도르시아 파마슈티컬스 리미티드 reassignment 이도르시아 파마슈티컬스 리미티드 권리의 전부이전등록 Assignors: 액테리온 파마슈티칼 리미티드
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
KR1020107024856A 2008-05-05 2009-05-04 레닌 억제제로서의 3,4-치환된 피페리딘 유도체 Expired - Fee Related KR101403311B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12652908P 2008-05-05 2008-05-05
US61/126,529 2008-05-05
US18830308P 2008-08-07 2008-08-07
US61/188,303 2008-08-07
PCT/CA2009/000611 WO2009135299A1 (en) 2008-05-05 2009-05-04 3, 4 - substituted piperidine derivatives as renin inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020137003332A Division KR20130029116A (ko) 2008-05-05 2009-05-04 레닌 억제제로서의 3,4-치환된 피페리딘 유도체

Publications (2)

Publication Number Publication Date
KR20100131007A KR20100131007A (ko) 2010-12-14
KR101403311B1 true KR101403311B1 (ko) 2014-06-05

Family

ID=41264366

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020107024856A Expired - Fee Related KR101403311B1 (ko) 2008-05-05 2009-05-04 레닌 억제제로서의 3,4-치환된 피페리딘 유도체
KR1020137003332A Withdrawn KR20130029116A (ko) 2008-05-05 2009-05-04 레닌 억제제로서의 3,4-치환된 피페리딘 유도체

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020137003332A Withdrawn KR20130029116A (ko) 2008-05-05 2009-05-04 레닌 억제제로서의 3,4-치환된 피페리딘 유도체

Country Status (23)

Country Link
US (1) US8889714B2 (cg-RX-API-DMAC10.html)
EP (1) EP2274295B1 (cg-RX-API-DMAC10.html)
JP (3) JP4790871B2 (cg-RX-API-DMAC10.html)
KR (2) KR101403311B1 (cg-RX-API-DMAC10.html)
CN (1) CN102015682B (cg-RX-API-DMAC10.html)
AU (1) AU2009243875B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0912388A2 (cg-RX-API-DMAC10.html)
CA (1) CA2722734C (cg-RX-API-DMAC10.html)
CO (1) CO6311081A2 (cg-RX-API-DMAC10.html)
CR (1) CR11809A (cg-RX-API-DMAC10.html)
DO (1) DOP2010000329A (cg-RX-API-DMAC10.html)
EA (1) EA020853B1 (cg-RX-API-DMAC10.html)
ES (1) ES2548134T3 (cg-RX-API-DMAC10.html)
IL (1) IL208467A (cg-RX-API-DMAC10.html)
MA (1) MA32296B1 (cg-RX-API-DMAC10.html)
MX (1) MX2010012067A (cg-RX-API-DMAC10.html)
MY (1) MY152042A (cg-RX-API-DMAC10.html)
NI (1) NI201000188A (cg-RX-API-DMAC10.html)
NZ (1) NZ589019A (cg-RX-API-DMAC10.html)
PL (1) PL2274295T3 (cg-RX-API-DMAC10.html)
SG (1) SG192543A1 (cg-RX-API-DMAC10.html)
SV (1) SV2010003723A (cg-RX-API-DMAC10.html)
WO (1) WO2009135299A1 (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2296653B1 (en) 2008-06-03 2016-01-27 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
AU2009326797B2 (en) * 2008-12-10 2012-12-13 Merck Canada Inc. 3,4 - substituted piperidine derivatives as renin inhibitors
TWI562977B (en) * 2010-11-05 2016-12-21 Bayer Ip Gmbh Process for the preparation of substituted n-(benzyl)cyclopropanamines by imine hydrogenation
UA112897C2 (uk) * 2012-05-09 2016-11-10 Байєр Фарма Акцієнгезелльшафт Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
RU2692485C2 (ru) 2014-04-02 2019-06-25 Интермьюн, Инк. Противофиброзные пиридиноны
CN107602381B (zh) * 2017-09-11 2021-03-16 陕西莱特光电材料股份有限公司 一种萘甲酸酯类衍生物及其制备方法
CN108033876A (zh) * 2017-12-20 2018-05-15 江汉大学 一种5-溴-2-氯苯甲醛的制备方法
WO2020109039A1 (en) 2018-11-28 2020-06-04 Basf Se Pesticidal compounds
EP4143167B1 (en) 2020-04-28 2024-05-15 Basf Se Pesticidal compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006069788A1 (en) 2004-12-30 2006-07-06 Novartis Ag Organic compounds

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5380758A (en) 1991-03-29 1995-01-10 Brigham And Women's Hospital S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof
US5703073A (en) 1995-04-19 1997-12-30 Nitromed, Inc. Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
PL193686B1 (pl) 1995-09-07 2007-03-30 Hoffmann La Roche Pochodne piperydyny, środki lecznicze zawierającepochodne piperydyny, sposoby wytwarzania tych pochodnych oraz zastosowanie pochodnych
US5994294A (en) 1996-02-02 1999-11-30 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
CA2270118A1 (en) 1996-11-01 1998-05-14 Nitromed Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
IT1295694B1 (it) 1996-11-14 1999-05-27 Nicox Sa Nitrossi derivati per la preparazione di medicamenti ad attivita antitrombinica
IT1292426B1 (it) 1997-06-27 1999-02-08 Nicox Sa Sali nitrati di ace-inibitori
KR100600550B1 (ko) 2000-10-20 2006-07-13 에자이 가부시키가이샤 질소 함유 방향환 유도체
KR100783863B1 (ko) 2002-04-29 2007-12-10 액테리온 파마슈티칼 리미티드 7-아릴-3,9-디아자바이사이클로(3.3.1)논-6-엔 유도체 및고혈압, 심혈관 질환 또는 신장 질환의 치료에서 레닌저해물질로써 이들의 용도
MXPA04012136A (es) 2002-06-27 2005-04-19 Actelion Pharmaceuticals Ltd Nuevos derivados de tetrahidropiridina como inhibidores de renina.
US20040204455A1 (en) 2003-04-10 2004-10-14 Cody Wayne Livingston Piperidine derivative rennin inhibitors
US20060217371A1 (en) 2003-04-28 2006-09-28 Olivier Bezencon Diazabicyclononene and tetrahydropyriddine derivatives as renin inhibitors
MXPA05011478A (es) 2003-04-29 2005-12-12 Actelion Pharmaceuticals Ltd Derivados de 1,2,3,6-tetrahidropiridina 3,4-disustituidos novedosos.
CA2521938A1 (en) 2003-04-30 2004-11-11 Actelion Pharmaceuticals Ltd 9-azabicyclo[3.3.1]non-6-ene derivatives with a heteroatom at the 3-position as renin inhibitors
MXPA05011497A (es) 2003-04-30 2005-12-15 Actelion Pharmaceuticals Ltd Derivados de tropano y su uso como inhibidores de la enzima de conversion de angiotensina (ace).
MXPA05011496A (es) 2003-04-30 2005-12-15 Actelion Pharmaceuticals Ltd Derivados de azabiciclononeno.
EP1622564A2 (en) 2003-05-02 2006-02-08 Actelion Pharmaceuticals Ltd. Diazabicyclononene derivatives
TW200513461A (en) 2003-10-01 2005-04-16 Speedel Experimenta Ag Organische verbindungen
CN1863773A (zh) 2003-10-09 2006-11-15 埃科特莱茵药品有限公司 四氢吡啶衍生物
JP2007508262A (ja) 2003-10-13 2007-04-05 アクテリオン ファマシューティカルズ リミテッド 新規ジアザビシクロノネン誘導体およびその使用
CA2540817A1 (en) 2003-10-23 2005-05-06 Olivier Bezencon Diazabicyclononene and tetrahydropyridine derivatives as renin inhibitors
US20070111989A1 (en) 2003-12-05 2007-05-17 Olivier Bezencon Novel diazabicyclononene derivatives and use
US20070135406A1 (en) 2003-12-05 2007-06-14 Olivier Bezencon Diazabicyclononene and tetrahydropyridine derivatives with a new side-chain
TW200613274A (en) * 2004-07-09 2006-05-01 Speedel Experimenta Ag Organic compounds
CA2577084A1 (en) 2004-08-25 2006-03-02 Olivier Bezencon Bicyclononene derivatives as renin inhibitors
WO2006021399A2 (en) 2004-08-25 2006-03-02 Actelion Pharmaceuticals Ltd Azabicyclononene derivatives as renin inhibitors
WO2006021403A1 (en) 2004-08-25 2006-03-02 Actelion Pharmaceuticals Ltd Bicyclononene derivatives
WO2006021401A2 (en) 2004-08-25 2006-03-02 Actelion Pharmaceuticals Ltd Bicylononene derivatives
WO2006058546A1 (en) 2004-12-01 2006-06-08 Actelion Pharmaceuticals Ltd Novel lactame derivatives as renin inhibitors
TW200634014A (en) 2004-12-08 2006-10-01 Actelion Pharmaceuticals Ltd Novel diazabicyclononene derivative
WO2006063610A1 (en) 2004-12-17 2006-06-22 Actelion Pharmaceuticals Ltd Heteroaryl substituted diazabicyclononene derivatives
GB0500784D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
CA2595986A1 (en) 2005-01-28 2006-08-03 Actelion Pharmaceuticals Ltd 7-{4-[2-(2,6-dichlor0-4-methylphenoxy)-ethoxy]phenyl}-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-(2,3-dimethylbenzyl)amides as inhibitors of renin for the treatment of hypertension
WO2006092268A1 (en) 2005-03-02 2006-09-08 Actelion Pharmaceuticals Ltd Bicyclic five-membered heteroaryl derivatives and their use as renin inhibitors
GB0504850D0 (en) * 2005-03-09 2005-04-13 Novartis Ag Organic compounds
WO2006103275A1 (en) 2005-03-31 2006-10-05 Speedel Experimenta Ag 3,4,5-substituted piperidines as renin inhibitors
TW200833687A (en) 2005-03-31 2008-08-16 Speedel Experimenta Ag Substituted piperidines
GB0510810D0 (en) 2005-05-26 2005-06-29 Novartis Ag Organic compounds
AU2006253805A1 (en) * 2005-05-27 2006-12-07 Actelion Pharmaceuticals Ltd. Novel piperidine carboxylic acid amide derivatives
GB0511063D0 (en) * 2005-05-31 2005-07-06 Novartis Ag Organic compounds
WO2006131884A2 (en) 2005-06-07 2006-12-14 Actelion Pharmaceuticals Ltd Thiazole substituted diazabicyclononane or-nonene derivatives as renin inhibitors
CA2615048A1 (en) 2005-07-22 2007-01-25 Merck Frosst Canada Ltd. Renin inhibitors
WO2007034406A1 (en) 2005-09-22 2007-03-29 Actelion Pharmaceuticals Ltd Pyrrolidine-3-carboxylic acid amide derivatives and their use as inhibitors of renin
WO2007034445A2 (en) 2005-09-26 2007-03-29 Actelion Pharmaceuticals Ltd Novel piperazine derivatives as renin inhibitors for cardiovascular events and renal insufficiency
WO2007049224A1 (en) 2005-10-25 2007-05-03 Actelion Pharmaceuticals Ltd Novel hexahydro- or octahydro-cyclopenta[c]pyrrole derivatives
JP5306821B2 (ja) 2005-12-30 2013-10-02 ノバルティス アーゲー レニン阻害剤としての3,5−置換ピペリジン化合物
EP1816122A3 (en) 2006-01-19 2007-09-19 Speedel Experimenta AG 3,4,5-substituted piperidines as therapeutic compounds
RU2425032C2 (ru) 2006-02-02 2011-07-27 Актелион Фармасьютикалз Лтд Вторичные амины в качестве ингибиторов ренина
CA2642424A1 (en) 2006-03-03 2007-09-07 Actelion Pharmaceuticals Ltd. Primary amines as renin inhibitors
NZ571595A (en) 2006-03-08 2010-06-25 Actelion Pharmaceuticals Ltd New amines
JP2010503682A (ja) 2006-09-18 2010-02-04 ビテ ファーマシューティカルズ, インコーポレイテッド レニン阻害剤としてのピペリジン誘導体
DE602007007664D1 (de) * 2006-11-17 2010-08-19 Merck Frosst Canada Inc Renininhibitoren
AU2008253519A1 (en) * 2007-05-24 2008-11-27 Merck Frosst Canada Ltd Novel case of renin inhibitors
JP2010535716A (ja) 2007-08-07 2010-11-25 メルク フロスト カナダ リミテツド レニン阻害剤
WO2009070869A1 (en) * 2007-12-04 2009-06-11 Merck Frosst Canada Ltd. Renin inhibitors
AU2009250299A1 (en) 2008-05-22 2009-11-26 Merck Frosst Canada Ltd 3, 4 - substituted piperidine derivatives as renin inhibitors
US20120190701A1 (en) 2009-08-18 2012-07-26 Merck Sharp & Dohme Corp. Renin inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006069788A1 (en) 2004-12-30 2006-07-06 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
CR11809A (es) 2011-01-10
CN102015682B (zh) 2014-07-16
IL208467A (en) 2014-07-31
JP5587246B2 (ja) 2014-09-10
NI201000188A (es) 2012-02-02
SG192543A1 (en) 2013-08-30
CN102015682A (zh) 2011-04-13
CA2722734C (en) 2013-11-05
MY152042A (en) 2014-08-15
SV2010003723A (es) 2011-01-24
MA32296B1 (fr) 2011-05-02
EP2274295A1 (en) 2011-01-19
EP2274295B1 (en) 2015-08-05
JP4790871B2 (ja) 2011-10-12
EA020853B1 (ru) 2015-02-27
WO2009135299A1 (en) 2009-11-12
JP2011519871A (ja) 2011-07-14
JP2011225580A (ja) 2011-11-10
CA2722734A1 (en) 2009-11-12
KR20100131007A (ko) 2010-12-14
AU2009243875A1 (en) 2009-11-12
CO6311081A2 (es) 2011-08-22
PL2274295T3 (pl) 2016-01-29
AU2009243875B2 (en) 2011-12-01
ES2548134T3 (es) 2015-10-14
US8889714B2 (en) 2014-11-18
DOP2010000329A (es) 2011-01-15
MX2010012067A (es) 2010-12-06
EP2274295A4 (en) 2012-03-28
KR20130029116A (ko) 2013-03-21
IL208467A0 (en) 2010-12-30
JP2011225579A (ja) 2011-11-10
BRPI0912388A2 (pt) 2017-09-26
NZ589019A (en) 2012-10-26
US20110053940A1 (en) 2011-03-03
JP5653842B2 (ja) 2015-01-14
EA201071269A1 (ru) 2011-06-30

Similar Documents

Publication Publication Date Title
JP5653842B2 (ja) レニン阻害剤としての3,4−置換ピペリジン誘導体
KR101214665B1 (ko) 트리아졸 유도체 또는 그의 염
JP6993357B2 (ja) Apjアゴニストとしての6-ヒドロキシ-5-(フェニル/ヘテロアリールスルホニル)ピリミジン-4(1h)-オン
JP6948322B2 (ja) Apj受容体のapjアゴニストとしてのヘテロアリールヒドロキシピリミジノン
JP2011520924A (ja) レニン阻害剤としての3,4−置換ピペリジン誘導体
CN101213184B (zh) 包含不饱和或环状连接基团的杂芳基取代的酰胺及其作为药物的用途
JP2005516950A (ja) 代謝型グルタミン酸受容体−5のヘテロアリール置換イミダゾールモジュレータ
CA2694410A1 (en) Pyridinoylpiperidines as 5-ht1f agonists
CN102656159A (zh) Cgrp受体拮抗剂
JP4851328B2 (ja) 新規なピリジン誘導体
TW200944512A (en) Hydroxyquinoxaline carboxamide derivatives
JP5149794B2 (ja) 飽和リンカー基を含有するヘテロアリール置換アミドおよび医薬としてのその使用
JP2025518047A (ja) TRPM3媒介性障害を治療するためのピラゾロ[1,5-a]ピリジン誘導体
TWI472524B (zh) 腎素抑制劑
JPWO2001057044A1 (ja) ピリドキサジン誘導体
HK1109626A (en) Nicotinamide pyridinureas as vascular endothelial growth factor (vegf) receptor kinase inhibitors

Legal Events

Date Code Title Description
A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

A107 Divisional application of patent
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20170519

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

FPAY Annual fee payment

Payment date: 20180523

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20190529

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20190529